Research Progress on Immunosenescence in Elderly Patients
with Advanced Non-small Cell Lung Cancer and Its Immunotherapy.
10.3779/j.issn.1009-3419.2025.102.28
- Author:
Na WANG
1
;
Yaning LUO
1
;
Haoyu LU
1
;
Siyuan CUI
1
;
Kui ZHAO
1
;
Fanming KONG
1
Author Information
1. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
- Publication Type:English Abstract
- Keywords:
Elderly patients;
Immunosenescence;
Immunotherapy;
Lung neoplasms
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Immunotherapy;
Lung Neoplasms/genetics*;
Immunosenescence;
Aged
- From:
Chinese Journal of Lung Cancer
2025;28(7):542-550
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer remains the leading cause of cancer-related incidence and mortality worldwide. Among its histological subtypes, non-small cell lung cancer (NSCLC) accounts for the majority of cases, representing the predominant pathological type. Notably, in the elderly population, NSCLC continues to be a major contributor to cancer-related deaths. With the global ageing population, immunosenescence has emerged as a key factor influencing the occurrence, progression, and the efficacy of immunotherapy of NSCLC. Immunosenescence refers to the age-related decline in immune system function, which manifests as alterations in both the quantity and functionality of immune cells. These include thymic involution, T cell exhaustion, epigenetic modifications, weakened immune responses, and a chronic low-grade inflammatory state. This review comprehensively analyzes the role of immunosenescence in elderly patients with advanced NSCLC and proposes potential therapeutic strategies to intervene in the immunosenescence process. By targeting immunosenescence, these strategies aim to inhibit the progression of NSCLC and improve the effectiveness of immunotherapy.
.
